Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,386
Views
3
CrossRef citations to date
0
Altmetric
Original Research

In vitro OP9-DL1 co-culture and subsequent maturation in the presence of IL-21 generates tumor antigen-specific T cells with a favorable less-differentiated phenotype and enhanced functionality

Sarah Bontea Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium;b Cancer Research Institute Ghent (CRIG), Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-0637-4893View further author information
ORCID Icon,
Stijn de Munterb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Lore Billietc Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Glenn Goetgelukb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Joline Ingelsc Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Hanne Jansenc Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Melissa Pillec Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Laurenz de Cockb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;d Department of Biomolecular Medicine, Ghent University, Ghent, BelgiumView further author information
,
Karin Weeningc Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Tom Taghonb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Georges Leclercqb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
,
Bart Vandekerckhoveb Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, BelgiumView further author information
&
Tessa Kerrea Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium;b Cancer Research Institute Ghent (CRIG), Ghent, Belgium;c Department of Diagnostic Sciences, Ghent University, Ghent, Belgium;e Department of Hematology, Ghent University Hospital, Ghent, BelgiumCorrespondence[email protected]
View further author information
 show all
Article: 1954800 | Received 12 Apr 2021, Accepted 08 Jul 2021, Published online: 25 Jul 2021

References

  • Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. New Engl J Med. 2019;380(1):45–17. doi:10.1056/NEJMoa1804980.
  • Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, Medeiros JJF, Rao-Bhatia A, Jaciw-Zurakowsky I, Marke R, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104-+. doi:10.1038/nature22993.
  • Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17(7):1301–1312. doi:10.1038/sj.leu.2402988.
  • Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB, Bleakley M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25(7):1064-+. doi:10.1038/s41591-019-0472-9.
  • Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser ADM, Pouw N, Debets R, Kieback E, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565–U98. doi:10.1038/nm.2128.
  • van Loenen MM, De Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R, Van Rood JJ, Falkenburg JHF, Heemskerk MHM. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A. 2010;107(24):10972–10977. doi:10.1073/pnas.1005802107.
  • Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MHM. In vitro generation of mature, naive antigen-specific CD8+ T cells with a single T-cell receptor by agonist selection. Leukemia. 2014;28(4):830–841. doi:10.1038/leu.2013.285.
  • Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology. 2017;6(3):e1283460. doi:10.1080/2162402X.2017.1283460.
  • Bonte S, De Munter S, Goetgeluk G, Ingels J, Pille M, Billiet L, Taghon T, Leclercq G, Vandekerckhove B, Kerre T, et al. T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources. Oncoimmunology. 2020;9(1):1727078. doi:10.1080/2162402X.2020.1727078.
  • Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
  • Zhou JH, Shen XL, Huang JP, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175(10):7046–7052. doi:10.4049/jimmunol.175.10.7046.
  • Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu ZY, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8(+) T cells. J Clin Invest. 2005;115(6):1616–1626. doi:10.1172/JCI24480.
  • Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–129. doi:10.1126/science.1129003.
  • Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–U325. doi:10.1038/nm.2446.
  • Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573–584. doi:10.1182/blood-2012-05-431718.
  • Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells. Proc Natl Acad Sci U S A. 2004;101(7):1969–1974. doi:10.1073/pnas.0307298101.
  • Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8(+) T cells for adoptive immunotherapy. Blood. 2008;111(11):5326–5333. doi:10.1182/blood-2007-09-113050.
  • Zeng R, Spolski R, Finkelstein SE, Oh SK, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201(1):139–148. doi:10.1084/jem.20041057.
  • Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D’hont I, et al. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. Haematologica. 2020;105(5):1306–1316. doi:10.3324/haematol.2019.222612.
  • Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, et al. Central memory self/tumor-reactive CD8(+) T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571–9576. doi:10.1073/pnas.0503726102.
  • Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317(5):620–631. doi:10.1016/j.yexcr.2010.12.017.
  • Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity. 2010;33(1):128–140. doi:10.1016/j.immuni.2010.06.014.
  • Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. 2017;23(1):18–27. doi:10.1038/nm.4241.
  • Wolfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, Schlegel PG. Primed tumor-reactive multifunctional CD62L(+) human CD8(+) T cells for immunotherapy. Cancer Immunol Immun. 2011;60(2):173–186. doi:10.1007/s00262-010-0928-8.
  • Verneris MR, Karimi M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103(8):3065–3072. doi:10.1182/blood-2003-06-2125.
  • Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013;43(11):2797–2809. doi:10.1002/eji.201343751.
  • Barber DL, Wherry EJ, Masopust D, Zhu BG, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–687. doi:10.1038/nature04444.
  • Huang JP, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258–267. doi:10.1097/01.cji.0000158855.92792.7a.
  • Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379–385. doi:10.1038/nm0402-379.
  • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305. doi:10.1172/JCI32103.
  • Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rivera GOR, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP, Paulos CM. Fueling cancer immunotherapy with common gamma chain cytokines. Front Immunol. 2019;10:263.
  • Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E. IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy. Cancer Res. 2015;75(24):5187–5193. doi:10.1158/0008-5472.CAN-15-1498.
  • Zhao YB, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoletic stem cells via notch signaling. Cancer Res. 2007;67(6):2425–2429. doi:10.1158/0008-5472.CAN-06-3977.
  • Billiet L, Goetgeluk G, Bonte S, De Munter S, De Cock L, Pille M, Ingels J, Jansen H, Weening K, Van Nieuwerburgh F. Human thymic CD10(+) PD-1(+) intraepithelial lymphocyte precursors acquire interleukin-15 responsiveness at the CD1a(-) CD95(+) CD28(-) CCR7(-) developmental stage. Int J Mol Sci. 2020;21(22):8785. doi:10.3390/ijms21228785.
  • Pouw N, Treffers-Westerlaken E, Kraan J, Wittink F, Ten Hagen T, Verweij J, Debets R. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immun. 2010;59(6):921–931. doi:10.1007/s00262-010-0818-0.
  • Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. The molecular basis of IL-21-mediated proliferation. Blood. 2007;109(10):4135–4142. doi:10.1182/blood-2006-10-054973.
  • Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR, Distinct A. Subset of self-renewing human memory CD8(+) T cells survives cytotoxic chemotherapy. Immunity. 2009;31(5):834–844. doi:10.1016/j.immuni.2009.09.015.
  • Alvarez-Fernandez C, Escriba-Garcia L, Vidal S, Sierra J, Briones J. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J Transl Med. 2016;14. doi:10.1186/s12967-016-0973-y.
  • Li Y, Cong YN, Jia MM, He QQ, Zhong HQ, Zhao Y, Li H, Yan M, You J, Liu J, et al. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nat Commun. 2021;12(1):951.
  • Chen YS, Yu F, Jiang YW, Chen JL, Wu K, Chen XX, Lin Y, Zhang H, Li L, Zhang Y, et al. Adoptive transfer of interleukin-21-stimulated human CD8+ T memory stem cells efficiently inhibits tumor growth. J Immunother. 2018;41(6):274–283. doi:10.1097/CJI.0000000000000229.
  • Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. Cell Rep. 2018;22(12):3175–3190. doi:10.1016/j.celrep.2018.02.087.
  • Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, et al. The checkpoint for agonist selection precedes conventional selection in human thymus. Sci Immunol. 2017;2(8):eaah4232. doi:10.1126/sciimmunol.aah4232.
  • Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol. 2005;17(2):195–201. doi:10.1016/j.coi.2005.02.002.
  • Lizee G, Overwijk WW, Radvanyi L, Gao JJ, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013;64:71–90.
  • Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou JH, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173(12):7125–7130. doi:10.4049/jimmunol.173.12.7125.
  • Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854. doi:10.1126/science.1076514.
  • Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71(10):3516–3527. doi:10.1158/0008-5472.CAN-10-3843.
  • Sabatino M, Hu JH, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128(4):519–528. doi:10.1182/blood-2015-11-683847.
  • Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, et al. Transferred WT1-reactive CD8(+) T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5(174). doi:10.1126/scitranslmed.3004916.
  • Fernandez I, Ooi TP, Roy K. Generation of functional, antigen- specific CD81 human T cells from cord blood stem cells using exogenous notch and tetramer- TCR signaling. Stem Cells. 2014;32(1):93–104. doi:10.1002/stem.1512.
  • Varnum-Finney B, Brashem-Stein C, Bernstein ID. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood. 2003;101(5):1784–1789. doi:10.1182/blood-2002-06-1862.
  • Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood. 2005;106(8):2693–2699. doi:10.1182/blood-2005-03-1131.
  • Taqvi S, Dixit L, Roy K. Biomaterial-based notch signaling for the differentiation of hematopoietic stem cells into T cells. J Biomed Mater Res A. 2006;79a(3):689–697. doi:10.1002/jbm.a.30916.
  • Seet CS, He CB, Bethune MT, Lie SW, Chick B, Gschweng EH, Zhu Y, Kim K, Kohn DB, Baltimore D, et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods. 2017;14(5):521-+. doi:10.1038/nmeth.4237.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.